Matthew D. Shortridge

Matthew D. Shortridge

Auto-generated profile, based on publicly available information

Matthew D. Shortridge

Department of Chemistry, University of Washington, Seattle, Washington 98195, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Science
Verified
Journal Article
Closed access
PDF file
PHParisa Hosseinzadeh
Parisa Hosseinzadeh
GBGaurav Bhardwaj
Gaurav Bhardwaj
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
MSMatthew D. Shortridge
Matthew D. Shortridge
TCTimothy W. Craven
Timothy W. Craven
DBDavid Baker
David Baker
Macrocycles by design: Macrocyclic peptides have diverse properties, including antibiotic and anticancer activities. This makes them good therapeutic leads, but screening libraries only cover a fraction of the sequence space available to peptides comprising D and L amino acids. Hosseinzadeh et al. achieved near-complete coverage in sampling the sequence space for 7- to 10-residue cyclic peptides and identified more than 200 designs predicted to fold into stable structures. Of 12 structures determined, nine were close to the computational models. They also sampled and designed 11- to 14-residue macrocycles, but without complete coverage. The designed macrocycles provide a path forward for engineering new therapeutics. Science , this issue p. 1461

24 April 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
MSMatthew D. Shortridge
Matthew D. Shortridge
MWMatthew J. Walker
Matthew J. Walker
TPTom Pavelitz
Tom Pavelitz
YCYu Chen
Yu Chen
WYWen Yang
Wen Yang
GVGabriele Varani
Gabriele Varani

27 November 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MSMatthew D Shortridge
Matthew D Shortridge
PWPaul T Wille
Paul T Wille
AJAlisha N Jones
Alisha N Jones
ADAmy Davidson
Amy Davidson
JBJasmina Bogdanovic
Jasmina Bogdanovic
GVGabriele Varani
Gabriele Varani
The HIV-1 trans-activator protein Tat binds the trans-activation response element (TAR) to facilitate recruitment of the super elongation complex (SEC) to enhance transcription of the integrated pro-viral genome. The Tat–TAR interaction is critical for viral replication and the emergence of the virus from the latent state, therefore, inhibiting this interaction has long been pursued to discover new anti-viral or latency reversal agents. However, discovering active compounds that directly target RNA with high affinity and selectivity remains a significant challenge; limiting pre-clinical development. Here, we report the rational design of a macrocyclic peptide mimic of the arginine rich motif of Tat, which binds to TAR with low pM affinity and 100-fold selectivity against closely homologous RNAs. Despite these unprecedented binding properties, the new ligand (JB181) only moderately inhibits Tat-dependent reactivation in cells and recruitment of positive transcription elongation factor (P-TEFb) to TAR. The NMR structure of the JB181–TAR complex revealed that the ligand induces a structure in the TAR loop that closely mimics the P-TEFb/Tat1:57/AFF4/TAR complex. These results strongly suggest that high-affinity ligands which bind the UCU bulge are not likely to inhibit recruitment of the SEC and suggest that targeting of the TAR loop will be an essential feature of effective Tat inhibitors.

2 February 2023 in ACS Chemical Biology
Verified
Journal Article
Closed access
MSMatthew D. Shortridge
Matthew D. Shortridge
BCBhawna Chaubey
Bhawna Chaubey
HZHuanyu J. Zhang
Huanyu J. Zhang
TPThomas Pavelitz
Thomas Pavelitz
VVVenkata Vidadala
Venkata Vidadala
GVGabriele Varani
Gabriele Varani

13 July 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MSMatthew D. Shortridge
Matthew D. Shortridge
GVGabriele Varani
Gabriele Varani